Embolic Pattern of Stroke Associated with Cardiac Wall Motion Abnormalities; Narrowing the Embolic Stroke of Undetermined Source Category

J Stroke Cerebrovasc Dis. 2020 Feb;29(2):104509. doi: 10.1016/j.jstrokecerebrovasdis.2019.104509. Epub 2019 Nov 20.

Abstract

Background: There is ambiguity regarding the role of left ventricle wall motion abnormalities (LVWMAs) as a potential cardioembolic source in patients, who satisfy embolic stroke of undetermined source (ESUS) criteria.

Methods and results: We analyzed prospectively collected data in 345 acute stroke patients, 185 (53.6%) stroke with atrial fibrillation (SwAF), and 160 (46.4%) stroke with LVWMA. LVWMA were younger (P = .003), had significantly higher frequency of stroke risk factors and lower ejection fraction (P < .001). No significant difference was found between the stroke pattern in SwAF and LVWMA except focal cortical, cortical-subcortical lesions were more frequent in LVWMA (P = .002). Mean wall motion score index (WMSI) was 1.523 (range 1.05-2.71) without any correlation between the severity of WMSI and multiple strokes (P = .976). In subgroup analyses vertical basal WMSI (P = .030) and vertical mid cavity WMSI (P = .010) was significantly related to branch arterial stroke. LVWMA 94 (65%) patients were on antiplatelet/anticoagulation compared to 47 (52.4%) with atrial fibrillation (AF), with no significant difference in stroke recurrence during 4 years follow-up (P = .15).

Conclusions: Patients with LVWMA who satisfy ESUS criteria, have stroke pattern on diffusion-weighted magnetic resonance imaging and risk of stroke recurrence similar to AF-related stroke despite being on appropriate antiplatelet medications. Further studies with anticoagulation therapy may be required in this group of patients to improve the high risk of recurrent stroke.

Keywords: Cardiac wall motion abnormalities; ESUS; MRI; embolic stroke.

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / complications*
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / physiopathology
  • Diffusion Magnetic Resonance Imaging
  • Female
  • Humans
  • Intracranial Embolism / diagnostic imaging
  • Intracranial Embolism / etiology*
  • Intracranial Embolism / prevention & control
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use
  • Predictive Value of Tests
  • Recurrence
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Stroke / diagnostic imaging
  • Stroke / etiology*
  • Stroke / prevention & control
  • Time Factors
  • Treatment Outcome
  • Ventricular Dysfunction, Left / complications*
  • Ventricular Dysfunction, Left / diagnosis
  • Ventricular Dysfunction, Left / drug therapy
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Function, Left*

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors